Roche Diagnostics (Indianapolis, Ind.) received clearance from the FDA to market its Elecsys proBNP immunoassay for risk stratification in congestive heart failure (CHF) and in acute coronary syndrome. The test was previously approved as the first fully automated test for detecting the level of NT-proBNP peptide as an aid in the diagnosis of CHF.

Elecsys is approved for use on the Roche Elecsys 1010, Elecsys 2010, and Modular Analytics 3170 immunoassay analyzers.

For more information, visit http://www.roche-diagnostics.us and http://www.roche.com.